Polymorphisms in the m-opioid receptor gene (OPRM1) are primary candidate sources of clinical variability in opioid therapy. Apart from the 118A4G single nucleotide polymorphism, nothing is known about the role of OPRM1 mutations in opioid therapy. The influence of the OPRM1 mutations on opioid pharmacodynamics was assessed in pooled data from 31 healthy volunteers obtained in previous studies with available plasma concentrations and pupil diameters after intravenous administration of morphine or morphine-6-glucuronide (M6G). A total of 24 candidate ORPM1 mutations were screened for and those found at an allelic frequency of at least 5% in the 31 subjects were analyzed for functional consequences, using population pharmacokinetic-pharmacodynamic modeling of the miotic effects of the opioids as a reliable and sensitive surrogate parameter of the central nervous opioid effects. Polymorphisms at an allelic frequency of X5% (n ¼ 310) were 118A4G in exon 1 (11.5%), the IVS2-31G4A (8.9%) and IVS2-691C4G (44.5%) SNPs in intron 2. The 118A4G SNP significantly increased the values of EC 50 by a factor of more than 2 (nonmutated: EC 50,morphine ¼ 30 nmol/l, EC 50,M6G ¼ 750 nmol/l, 118G carriers: EC 50,morphine ¼ 66 nmol/l, EC 50,M6G ¼ 1650 nmol/l), whereas the IVS2-691C4G SNP had no effect. Based on morphine and M6G, the present analysis encourages focusing on the 118A4G SNP when investigating the role of OPRM1 mutations for the activity of opioid analgesics. Other OPRM1 mutations are probably less important either owing to low allelic frequency or due to poor indications for functional consequences. This applies to opioid potency in the context of opioid therapy but not to pain processing or substance addiction, in which opioid receptors are involved but other or additional OPRM1 mutations may be important.
Introduction
The human m-opioid receptor coded by the OPRM1 gene 1 is the major site of action 2 of most clinically used opioid analgesics. Polymorphisms in the m-opioid receptor are therefore a primary candidate source for pharmacogenetic variability of the clinical effects of opioids. Functional associations with opioid therapy have so far mainly focused on the 118A4G single nucleotide polymorphism (SNP) located in exon 1 of the gene. Morphine 3 and its active metabolite www.nature.com/tpj morphine-6-glucuronide (M6G) 3, 4 constricted pupils with a decreased potency and produced smaller analgesic effects 5, 6 in carriers of the mutated OPRM1 118G allele as compared to non-carriers. Patients carrying the mutated 118G allele required higher doses of morphine 7 or alfentanil for pain therapy. 8 Case reports support the functionality of the 118A4G SNP, for example, reports about a carrier of the 118G allele who tolerated very high plasma M6G well, whereas a non-carrier of the mutation (wild type) suffered from opioid toxicity, 9 and about a 118G carrier nonresponding to morphine pain therapy. 10 While the functional consequence of the 118A4G SNP appears to be well documented clinically, the role of other OPRM1 mutations in clinical opioid therapy has been rarely investigated. Several OPRM1 polymorphisms are found at higher frequency, 11 and therefore a functional consequence would be relevant for opioid therapy. For example, the IVS2-691C4G SNP in intron 2 is found at an allelic frequency of more than 40% but its functional role has never been investigated. The purpose of the present assessment was to estimate which OPRM1 mutations in addition to the 118A4G SNP would merit a closer look for their consequences for clinical opioid therapy. The approach was to assess the allelic frequency of several OPRM1 polymorphisms in a greater random sample of subjects and to subsequently assess the functional role of those mutations that are found more frequently in a pooled data set of mitotic effects of morphine and M6G obtained in several previous studies 3, 4, 12, 13 that focused on a single SNP or had a non-pharmacogenetic aim.
Methods
By using a pooled data set of effects produced by morphine and M6G, the sample size of carriers of OPRM1 mutations was increased. Thus, the influence of frequent OPRM1 mutations on opioid pharmacodynamics was assessed in pooled data from 31 of these subjects (Table 1) , who had participated in one or more previous studies, 3, 4, 12, 13 with available plasma concentrations and pupil diameters after intravenous administration of morphine or M6G (Figure 1 ). In addition, to estimate the allelic frequency of the OPRM1 polymorphisms in a random sample of subjects, 279 unrelated volunteers were genotyped. Thus, a total of 310 unrelated subjects, including the 31 subjects mentioned above, were genotyped for 24 OPRM1 mutations that had been identified previously, 11 and were presently selected because they had been proposed to be of functional importance or cause an amino-acid exchange or were just reported to be frequent. 14, 15 All subjects had given written informed consent for genotyping and approval from the University of Frankfurt Medical Faculty Ethics Review Board had been obtained.
Genotyping DNA was extracted from heparinized blood samples (10 ml) using the QIAamp DNA Mini Kit (QUIAGEN, Hilden, Germany). Genotyping for 24 OPRM1 mutations was performed on a PSQ 96MA device (Pyrosequencing AB, Uppsala, Sweden) as described previously using established Pyrosequencing TM assays. 16 The allelic frequencies observed in the 31 selected subjects were compared to those observed in the random sample of 279 subjects by means of Fisher's exact test. In addition, the correspondence between the observed number of homozygous and heterozygous individuals and that expected from the Hardy-Weinberg equilibrium was assessed separately for the 31 selected subjects and the random sample of 279 subjects, using the w 2 -test. The sequencing results were submitted to haplotype analysis using the HAPLOTYPER computer software for Linux (Harvard University, MA, USA 17 ). The subsequent analysis of functional consequences focused on OPRM1 polymorphisms found at a frequency of at least 5%, a value inspired by the frequency of functionally distinct cytochrome P450 2D6 phenotypes based on genetic polymorphisms. 18 Analysis of functional consequences of frequent OPRM1 mutations The plasma concentrations from the four previous studies 3, 4, 12, 13 had all been analyzed by the same staff in the same laboratory on the same equipment using the same validated LC-MS/MS assay. 4 Addition of quality control samples and permanent stability tests of the analytes ensure the goodness of the validated method. Thus, measurement of the same samples at different times (e.g. once every year) resulted in the same concentrations of the analytes. The coefficient of correlation over the concentration range of morphine or M6G from 0.5 to 1000 ng/ml for the measured sequences was at least 0.99. The intraday and interday variability was o10%. From studies involving the coadministration of other drugs along with the opioids, 12, 13 only the data from the opioid-only condition were used in the present analysis.
If OPRM1 mutations are of functional relevance, the most likely parameters they affect are the potency and/or the efficacy of the opioid. To calculate these parameters, pupil diameters were related to the concentrations of morphine and M6G at effect site by a sigmoid E max -model for competitive agonism: where E 0 is the pupil diameter before administration of the opioid, E max the pupil diameter at maximum possible induced miosis induced by the opioid that acts as full agonists at m-opioid receptors, EC 50,morphine and EC 50,M6G describe the potency of the opioids and are the concentrations of morphine and M6G, respectively, at half-maximum effect, and g morphine and g M6G the shape factors of the concentration response relationship for morphine and M6G, respectively. The value of E 0 of 6.7 (and 13% coefficient of variation) was not estimated by equation 1 but the observed baseline pupil size and interindividual variability were taken.
The modeling process repeatedly employed goodness-offit procedures as follows: Two alternative models were applied to the data, (i) one model without inclusion of the genotype (or another parameter such as an interindividual variance assigned to a specific parameter, or sex assigned to a parameter to be tested for sex differences), and (ii) one Lötsch et al. 4 Skarke et al. 3 Skarke et al. 12 Skarke et al. 100% overlap with the IVS2 691C4G SNP. The 17C4T SNP was not found in the 31 subjects.
OPRM1 polymorphisms and opioid potency J Lötsch and G Geisslinger model that included the genotype (or the respective other parameter). Thus, the data were fitted twice, one time with each model. The resulting fits were compared with each other. Goodness-of-fit was assessed by (i) the likelihood ratio test, using minus two times the log likelihood as statistical parameter of the goodness-of-fit, and using the w 2 approximation with the number of degrees of freedom equal to the difference in the number of terms between two models to compare the two fits (a-level 0.05), (ii) the median absolute weighted residuals (MDAWR), calculated as (measuredÀpre-dicted)/predicted, and the mean of the individual mean absolute weighted residuals (MAWR), and (iii) visual inspection of the fits versus observed data. From these comparisons, the model that provided a better fit of the data was selected while the alternative model was discarded. This applies also to the selection of modeling the miotic effects with an additive model, that is, as differences to baseline, rather than with a multiplicative model, that is, as percent changes from baseline, although the difference between models with respect to goodness-of-fit was not substantial.
The effect of the mutation on EC 50 was assessed as follows: First, it was checked whether EC 50 varies between individuals. This was performed by modeling the interindividual variability as normally distributed: P i ¼ y i;TV þ Z i , where P i is the value of the parameter of the individual, y i,TV is the typical value (TV) of this parameter in the population, and Z is a variable accounting for the interindividual variability, with mean zero and variance o 2 . This provided a better fit than the assumption of a log-normal distribution of EC 50 .
After the process of applying a goodness-of-fit judgment it was assured that the EC 50 varied interindividually, which was then followed by a check to see whether a particular OPRM1 genotype significantly contributed to that interindividual variability. In other words, the approach to the functional consequences of OPRM1 mutations was to explain significant portions of the interindividual variance in the parameters of the opioid effect versus concentration relationship by these pharmacogenetic factors. For this, 'EC 50 ' in equation 1 was replaced by 'EC 50 Á 1' for noncarriers of the particular mutation tested, and by 'EC 50 y' for carriers of the particular mutated allele. If the fit of the data was significantly improved by introducing ya1, then the influence of the tested OPRM1 mutations on opioid potency was statistically proven. It was also checked whether different parameters 'y' for morphine and M6G improved the fit, and again goodness-of-fit assessment was applied. The effect of OPRM1 mutations on the efficacy, that is, on E max , was analyzed analogously as for the potency EC 50 .
The data set was divided into subsets that allowed for the functional assessment of particular mutations without confounding the results by other coexistent OPRM1 mutations. Specifically, for each polymorphism a data set was selected that contained only subjects not carrying any other of the 24 OPRM1 mutations. This resulted in separate data sets for 118A4G and IVS2 691G4C but these data sets were small and lacked IVS2 31G4A carriers. Therefore, we created another data set that did not contain carriers of the 118G allele. Finally, the maximum available information was used 2 4 6 8 10 12 14 16 18 0 2 4 6 8 10 12 14 16 18 0 2 4 6 8 10 12 14 16 Plasma Pupils Figure 1 The data set of the present analysis was pooled from four previous studies. The figure shows the means (and s.d.) of the observed plasma concentrations and pupil sizes after administration of morphine and M6G in these studies. M6G plasma concentrations after morphine administration are not shown for clearer presentation but they were part of the analysis. Note that some subjects had participated in more than one study (Table 2) , which resulted in a total number of 31 subjects in the pooled data set. in an analysis of the complete data set comprising 31 subjects (Table 1) . To obtain the opioid concentrations at effect site, C e , semiparametric pharmacokinetic-pharmacodynamic (PK/PD) modeling 19 was used (Figure 2 ). This described the plasma concentrations by linear splines, that is, as successive concentrations connected by a straight line, a procedure that minimizes the consequences of badly fitted pharmacokinetics for the fit of the opioid pharmacodynamics, provided a short sampling interval is observed as in the present data set. The effect of the opioid was assumed to relate to C e at a theoretical effect compartment. [20] [21] [22] Equilibration between this effect compartment and the plasma compartment was assumed to follow a first-order transfer process with a rate constant k e0 . Thus, the time course of C e , C e (t), is described by
where C p (t) is the time course of the plasma concentration, which is convoluted (denoted by an asterisk) with the firstorder transfer function k e0 Á e Àke0Át characterized by the rate constant k e0 . A log-normally distributed interindividual variance of the model parameters was used: P i ¼ y i;TV Á e Z i , where P i is the value of the parameter of the individual, y i,TV is the typical value (TV) of this parameter in the population, and Z is a variable accounting for the interindividual variability, with mean zero and variance o 2 . The variance model was selected by goodness-of-fit judgment.
Further technical details of the fitting procedure were as follows: Modeling was carried out with the NONMEM V (version 1.1, GloboMax LLC, Hanover, MD, USA). The residual error e was modeled using an additive error model, again because this provided the best fit. Calculations were performed using 'first-order conditional estimation' and 'Z-e interaction' as described elsewhere. 23 Morphine-3-glucuronide (M3G, the main metabolite of morphine) was ignored because M3G administered at doses three times greater than the amount of M3G formed from clinically active doses of morphine was reported to lack clinical activity and to leave the effects of morphine completely unaffected. 24, 25 Finally, sex differences in opioid potency or efficacy were checked for in the same manner as genotype differences. As the results of this check were negative, men and women did not differ in the assessed parameters, sex differences were not further regarded.
Results

Selection of OPRM1 SNPs based on allelic frequency
The results of genotyping for 24 OPRM1 mutations in the 31 subjects from which data for further analysis were available are shown in Table 2 . Three of the 24 SNPs were found at an allelic frequency of at least 5%, the 118A4G mutation in exon 1, and the IVS2-31G4A and IVS2-691C4G SNPs in intron 2 ( Table 1 ). The other SNPs were rarer than 5%, which corresponded to the reported SNP frequencies (Table 2) except for À172G4T and 17C4T SNP that were presently found only at frequencies of 4.2% and 0.8%, respectively, but have a reported frequency of more than 5% (Table 2) . Therefore, the Pyrosequencing TM results for these SNPs were verified by conventional DNA sequencing in 70 randomly selected samples, which resulted in 100% agreement.
The allelic frequencies of the 24 SNPs did not differ between the 31 selected subjects and the random sample of 279 subjects (Fisher's exact test: P40.05). The distribution of with a first-order transfer function between plasma and effect site, with a rate constant k e0 (equation 2). (c) To the obtained concentrations at effect site, C e , the miotic effects were modeled using a sigmoid E max model (for agonistic effects of two opioids, morphine and M6G, see equation 1), which provided the values of EC 50 and E max denoting potency and efficacy of the opioids, respectively, which were the target parameters of the present analysis. The shown data are an example from one subject after administration of M6G.
OPRM1 polymorphisms and opioid potency J Lötsch and G Geisslinger Table 2 Allelic frequencies of 24 single SNPs in the OPRM1 gene and allelic frequency of those haplotypes that were more frequent than 5%, obtained in a random sample of 310 subjects. In addition, the reported ranges of the SNPs' allelic frequencies are given homozygous carriers and heterozygous subjects corresponded with the expectations according to the HardyWeinberg equilibrium for both the 31 selected subjects and the random sample of 279 subjects (details not shown). The HAPLOTYPER 17 software identified 25 OPRM1 haplotypes with respect to the 24 tested DNA position. The allelic frequencies of the more frequent haplotypes are given in Table 2 .
The three more frequent SNPs were equally distributed among studies and sufficiently often found in the first two studies that provided the higher quality data. The occurrence of the variant IVS2-31A allele in intron 2 completely overlapped with the occurrence of the variant IVS2-691G allele making a separate analysis of the IVS2-31G4A SNP impossible.
Functional consequences of the selected SNPs
The results of the assessment of functional assessments are presented in Table 3 . The 118A4G mutation significantly increased the values of EC 50 by a factor of more than 2 (Figure 3) , resulting in an improvement of fit at Po0.001 (Table 3) . Allowing this decrease in potency to be separately estimated for morphine and M6G did not improve the fit, indicating that the consequences of the SNP were similar for both opioids. In contrast, the IVS2-691C4G SNP or the concomitant occurrence of IVS2-31A and IVS2-691G had no significant influence on the EC 50 (Figure 3) . That is, the fits were not significantly improved when the EC 50 was allowed to vary between carriers and non-carriers of the respective SNPs. This negative result was also obtained with the data set that did not contain carriers of the 118G allele (not shown). The efficacy, E max , was not affected by any OPRM1 Ce = opioid concentration at effect site [nM] 1 10 100 1000 10000
Figure 3 Changes in miotic opioid potency in relation to the presence of OPRM1 polymorphisms as predicted from the present pooled data. Only with the 118G allele a right shift of the effect versus concentration relationship is expected, whereas other frequent mutations are unlikely to affect the opioid pharmacodynamics. A probably even more pronounced right shift would be expected with mutations affecting the third intracellular loop but these polymorphisms are almost never found (frequency oo1%). Table 3 Values of opioid potency estimated using equations (1) and (2) and different subsets of data as well as the full data set 118A4G IVS2-31A and IVS2-691G IVS2-691C4G
Carriers y is the factor with which the EC 50 was multiplied in carriers of a specific mutation, for example, the EC 50 of morphine is 30 nmol/l in non-mutated persons, and 30 nmol/ l Á 2.2 ¼ 66 nmol/l in carriers of the 118G allele, when taking the estimate from the full data set, which is preferable because it makes maximum use of available information.
a y was estimated to be 1 by goodness-of-fit criteria, that is, its introduction into the equation did not improve the fit. 'Not mutated' means none of the 24 OPRM1 mutations were (Table 2) found in the subjects belonging to this group.
OPRM1 polymorphisms and opioid potency J Lötsch and G Geisslinger 207 mutation. The other results of the PK/PD modeling were the transfer half-life between plasma and effect site, calculated as ln(2)/k e0 , which was 2.7 and 5 h for morphine and M6G, respectively, the value of E max of 2.3 mm and a coefficient of variation among subjects (CV%) of 38%, and the values of g morphine and g M6G of 1.8 and 2.2, respectively, without interindividual variability.
Discussion
Among many OPRM1 mutations, five have reported and/or presently found allelic frequency of at least 5%. A frequency of 5% was considered the minimum than can become important for the therapeutic use of opioids, which is in analogy to the frequency of functionally distinct cytochrome P450 2D6 phenotypes based on genetic polymorphisms. 18 This might differ when focusing on drug addiction, where a less frequent allele might explain why a particular individual carries a higher risk of becoming addicted. For consequences in the clinical use of opioids, however, a mutation should be found more frequently to merit the additional effort of routine genotyping. This frequencybased selection provided a basis to target the functional assessment of OPRM1 mutations in the context of opioid therapy on a few SNPs.
The 118A4G SNP was verified to be of functional consequence, leading to a decrease in the potencies of morphine and M6G to produce miosis. The SNP has been previously reported to decrease the clinical potency of alfentanil, 8 morphine 3,7 and M6G. [3] [4] [5] [6] An altered responsiveness of the hypothalamic-pituitary-adrenal axis in 118G carriers 26, 27 further supports a functional consequence of the 118A4G SNP and probably affects a greater range of other clinical opioid effects. Possible therapeutic consequences of the 118A4G SNP are still controversial. An increased therapeutic range of opioids, as suggested from the observation of fewer vomits in six 118G carriers as compared to six non-carriers, 3 and from the good tolerance of high plasma M6G in a patient homozygous for the 118G allele, 9 has been contradicted in a study that included only four heterozygous 118G carriers and compared them with 12 non-carriers 6 ). The 118A4G OPRM1 SNP causes an amino-acid exchange from asparagine at position 40 of the m-opioid receptor protein, which is highly preserved among species, to aspartate (i.e., N40D receptors). Beta-endorphin was reported to bind three times tighter at the mutated receptors than at the non-mutated N40 receptors in transfected AV-12 cells, whereas morphine binding was not affected. 28 However, others found no altered ligand binding and receptor signaling at N40D m-opioid receptors on HEK293 cells. 29, 30 Thus, the molecular mechanism underlying the repeatedly observed decreased clinical effects of opioids in 118G carriers is still not completely understood. Recently, a consequence of the OPRM1 118G allele for both mRNA and protein yield has been proposed. 31 That is, in human brain tissue the A118 mRNA allele was 1.5-to 2.5-fold more abundant than the G118 allele, and cDNA transfection into CHO cells produced 1.5-fold lower mRNA levels for the 118G allele than for the 118A allele and more than 10-fold lower OPRM1 protein levels associated with the 118G allele. 31 The composition of the data set to analyze the functional consequences of the most frequent OPRM1 mutation, the IVS2-691C4G SNP in intron 2, was similarly good as that on which the positive functional assignment of the 118A4G SNP was based. Nonetheless, there was no hint that the IVS2-691C4G SNP has a functional consequence, whereas the functional consequences of the 118A4G SNP were identified. Thus, a rejection of functional consequence is very well supported by the present data. This does not apply to the IVS2-31G4A SNP in intron 2, for which a data set not confounded by other SNPs could not be created because all subjects carrying this SNP also carried the IVS2-691C4G SNP. The rejection of a functional consequence of the IVS2-31A in the presence of IVS2-691G, together with the definitely negative functional association of the IVS2-691G allele, discourages an assumption of a functional consequence of IVS2-31G4A mutation.
The 17C4T SNP was presently found only at a frequency of 0.8% in the 310 samples and not at all in the 31 subjects available for functional analyses, but elsewhere it had been observed at up to 10%, 28, 32, 33 whereas in another report it was as rare as it was presently (allelic frequency of 1% in 51 subjects 34 ). The SNP causes an amino-acid exchange from alanine to valine at position 6 of the receptor protein, a position not so well preserved among species (valine in cattle, rhesus monkey and guinea pig, aspartate in pig, glycin in rat and mouse). Suggestions of a functional consequence of the 17C4T SNP come from studies on substance addiction but there are more negative than positive functional associations (see for example Gelernter et al.
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). The present analytical approach of pooling data from previous studies may have resulted in limitations because of (1) the retrospective analysis, (2) the small numbers for the individual mutations and (3) the administration of different substances. The most important potential limitation relates to incomparability of the merged data sets because of a different measurement of pharmacodynamic target variables or of plasma concentrations. Both could be excluded. That is, the pupil size measurements had not been observed to be biased among different studies during the last few years, when they had been conducted by the same observers by means of identical equipment in an identical laboratory setup under identical conditions of illumination. Furthermore, the constant outcome of the analysis of the plasma concentrations has been verified by the routine inclusion of quality control samples into the analytics and by occasional re-analysis of samples from previous studies, which always produced similar results. In addition, the presently applied statistical procedure of population modeling with NONMEM is well suited to extract the maximum of meaningful information from heterogeneous and pooled data sets 36 in terms of plasma concentrations, magnitude of effects and observation period. Indeed, the analysis of the OPRM1 polymorphisms and opioid potency J Lötsch and G Geisslinger consequences of the variant OPRM1 118G allele for the effects of morphine and M6G in the greater data set showed that the SNP affects both morphine and M6G. This had not been observed in a smaller data set where it appeared that the 118A4G SNP preferentially affects M6G. 4 Although the consequences of the SNP for morphine have already been reported, 3 the present result in the greater data set obtained by pooling emphasizes the benefit of a grater data set for pharmacogenetic analyses. Taken together, the retrospective pooled data approach of the study is unlikely to have confounded the results. In contrast, it provided a data set great enough to judge the role of more OPRM1 SNPs than the single studies.
We started from multiple candidate human OPRM1 mutations for which a judgment of their potential role in opioid therapy was unclear. Based on allelic frequency, reported and directly assessed in a random sample of 310 subjects, we selected among the many OPRM1 polymorphisms five candidates to take a closer look at the chosen context of clinical opioid therapy. Three of the selected polymorphisms could be analyzed for functional consequences for opioid pharmacodynamics in pooled data from four previous studies. The results of the present analysis are in support of a functional consequence of the OPRM1 118A4G SNP for the clinical actions of opioid analgesics. Its allelic frequency with 12% makes it important for 1/8 of the patients in pain treated with opioids. In contrast, the present assessment shows that other OPRM1 mutations are either too rare or there is no hint that they might be important for clinical opioid therapy, with reservations about this judgment regarding the elsewhere more frequently found (45%) À172G4T and 17C4T SNPs. The analysis showed that the IVS2-691C4G SNPs in intron 2 does not affect opioid pharmacodynamics. Furthermore, the analysis discourages a functional association for the IVS2-31G4A SNP. Taking this together with the observed allelic frequency of other OPRM1 SNPs, the present analysis encourages focusing on the 118A4G SNP when investigating the role of OPRM1 mutations for opioid therapy in order to judge whether OPRM1 genotyping would be a useful addition in the conduct of pain therapy.
